Heart Failure

A recent analysis of the COAPT trial, published this spring in the Journal of the American College of Cardiology, suggests patients with symptomatic heart failure (HF) and secondary mitral regurgitation (MR) might see better mental and physical outcomes if they’re treated with edge-to-edge transcatheter mitral valve repair (TMVR) in lieu of standard therapy.

The risk of peripartum cardiomyopathy (PPCM) is up to five times higher in mothers who undergo common fertility treatments like intracytoplasmic sperm injection (ICSI) and in vitro fertilization (IVF), according to data presented at Heart Failure 2019 in Athens.

Results from the FDA’s latest investigation into Abiomed’s Impella RP system are in—and, with a couple of caveats, they’re positive.

A six-week online training course centered around living with an implantable cardioverter-defibrillator (ICD) helped alleviate anxiety in heart failure patients who were apprehensive about their devices.

The Heart Rhythm Society issued a first-ever consensus statement on the evaluation, risk stratification and management of arrhythmogenic cardiomyopathy at its annual conference in San Francisco this spring.

The prevalence of heart failure (HF) in the U.S. is increasing hand-in-hand with rising rates of diabetes and obesity, according to a recent analysis, and HF-related CVD death rates have followed suit—most notably in younger adults.

Heart disease is now the leading cause of maternal deaths in the U.S., the American College of Obstetricians and Gynecologists (ACOG) reported in early May, prompting the organization to publish a comprehensive guide on pregnancy and CVD.

Individuals with heart failure with preserved ejection fraction (HFpEF) and atrioventricular block might benefit more from cardiac resynchronization therapy (CRT) than conventional right ventricular (RV) pacing, according to research published in JACC: Heart Failure.

The FDA has cleared two new drugs, tafamidis and tafamidis meglumine, for the treatment of cardiomyopathy caused by a rare disorder known as transthyretin-mediated amyloidosis (ATTR-CM).

Research out of the University of Manchester suggests Tadalafil (Cialis)—an erectile dysfunction drug that falls in the same class as Viagra—could slow and possibly reverse the progression of heart failure (HF).

Five milligrams of rivaroxaban per day added to a patient’s standard therapy for heart failure (HF) and coronary artery disease (CAD) could reduce that patient’s risk of future thromboembolic events, researchers reported in JAMA Cardiology April 24.

The same genetic variants that have been uncovered in patients with two other types of cardiomyopathy are also present in an uncommonly high proportion of people with cancer therapy-induced cardiomyopathy (CCM), researchers reported in Circulation.